SERPINB4 Antibody

What is SERPINB4 and what is its fundamental biological role in experimental systems?

SERPINB4, also known as squamous cell carcinoma antigen 2 (SCCA-2) or leupin, is a serine protease inhibitor that plays significant roles in both oncogenesis and immunity. It functions primarily by inhibiting chymotrypsin-like serine proteases including Chymase, Cathepsin G, and Der P . In experimental systems, SERPINB4 has been demonstrated to modulate the host immune response against tumor cells through its protease inhibition properties . Unlike its close homolog SERPINB3 (which primarily inhibits papain-like cysteine proteases), SERPINB4's substrate specificity is dictated by differences in the Reactive Center Loop (RCL) region, particularly in the "variable region" from P7 to P5' corresponding to catalytic residues of targeted proteases .

In research contexts, SERPINB4 is frequently studied as a potential biomarker in cancer progression, particularly in squamous cell carcinomas, where its elevated expression correlates with more advanced disease stages . When designing experiments involving SERPINB4, researchers should consider its often co-expressed paralog SERPINB3, with which it shares 92% amino acid sequence identity .

How can researchers effectively differentiate between SERPINB4 and its highly homologous paralog SERPINB3?

Effectively differentiating between SERPINB4 and SERPINB3 remains challenging due to their 92% amino acid sequence identity . Methodologically, researchers should employ antibodies that specifically target the RCL region, where these proteins show significant differences that account for their distinct protease specificities .

When performing antibody-based experiments, validation should include:

• Western blot analysis with recombinant proteins of both SERPINB3 and SERPINB4 to confirm antibody specificity

• Immunohistochemical validation using tissue samples known to differentially express these proteins

• Utilization of specific monoclonal antibodies such as clone 10C12 for SERPINB4 detection, which has been validated against recombinant proteins

For mRNA-based detection methods, primers should be designed to target regions of sequence divergence, particularly within the variable region of the RCL. Additionally, researchers should consider that these proteins are frequently co-expressed in tissues including uterus, esophagus, lung, prostate, testis, and trachea, which may necessitate additional specificity controls in experimental designs .

What are the optimal sample preparation protocols for SERPINB4 antibody-based detection in different experimental contexts?

Sample preparation for SERPINB4 antibody detection varies by application and should be optimized based on experimental objectives:

For Western Blot applications:

• Cell lysates should be prepared using RIPA buffer supplemented with protease inhibitors to prevent degradation

• Samples should be denatured at 95°C for 5 minutes in reducing conditions

• For optimal detection, load 20-30 μg of total protein per lane

• SERPINB4 has a predicted molecular weight of 45 kDa, which should be confirmed during analysis

For Immunohistochemistry on paraffin-embedded tissues:

• Formalin-fixed, paraffin-embedded tissue sections should be subjected to heat-induced epitope retrieval (HIER) using citrate buffer (pH 6.0)

• A dilution of 1:100 has been validated for commercial antibodies like ab197096

• Counterstaining with hematoxylin provides optimal visualization

• Include positive control tissues such as human fetal pancreas which has been validated for SERPINB4 expression

For cellular immunofluorescence:

• Fixation with 4% paraformaldehyde followed by permeabilization with 0.1% Triton X-100

• Blocking with 5% normal serum from the same species as the secondary antibody

• Overnight incubation with primary antibody at 4°C at optimized dilutions (typically 1:200-1:500)

• Include DAPI counterstaining for nuclear visualization

In all applications, researchers should validate antibody specificity using appropriate positive and negative controls, including SERPINB4-overexpressing cells and SERPINB4-knockout or knockdown systems.

How should researchers troubleshoot non-specific binding when using SERPINB4 antibodies?

When encountering non-specific binding with SERPINB4 antibodies, researchers should implement a systematic troubleshooting approach:

• Antibody validation:

  • Confirm antibody specificity using recombinant SERPINB4 protein

  • Test for cross-reactivity with SERPINB3 using purified proteins

  • Consider using antibodies with >95% purity by SDS-PAGE like PA5-37051

• Protocol optimization:

  • Increase blocking stringency (5-10% BSA or normal serum)

  • Optimize antibody dilution through titration experiments

  • Extend washing steps (at least 3x10 minutes with gentle agitation)

  • Reduce primary antibody incubation time or temperature

• Sample-specific considerations:

  • For tissues with high endogenous peroxidase activity, include a quenching step

  • Pre-absorb antibodies with tissue homogenates from species being tested

  • Consider using monoclonal rather than polyclonal antibodies when high specificity is required

• Controls implementation:

  • Include isotype controls matched to the primary antibody

  • Perform experiments with secondary antibody only

  • Include SERPINB4-knockout or siRNA knockdown samples as negative controls

  • Use competing peptide controls to verify binding specificity

When troubleshooting persistent cross-reactivity with SERPINB3, consider using specialized monoclonal antibodies like clone 10C12 that have been validated for specific detection of SERPINB4 over SERPINB3 .

How can SERPINB4 antibodies be utilized to investigate its role in cancer immunotherapy research?

SERPINB4 antibodies serve as crucial tools in investigating the emerging role of this protein in cancer immunotherapy research. Recent studies have identified that mutations in SERPINB4 are associated with improved survival following anti-CTLA4 immunotherapy in melanoma patients . To leverage SERPINB4 antibodies in this research area:

• Mutation-specific detection approaches:

  • Design immunoprecipitation protocols using SERPINB4 antibodies followed by mass spectrometry to identify specific mutations

  • Develop custom antibodies targeting common SERPINB4 mutational hotspots identified in melanoma patients

  • Implement proximity ligation assays (PLA) to investigate altered protein-protein interactions resulting from SERPINB4 mutations

• Functional immunotherapy correlation studies:

  • Perform immunohistochemistry on pre- and post-treatment tumor biopsies to quantify SERPINB4 expression changes during immunotherapy

  • Combine with multiplex immunofluorescence to correlate SERPINB4 expression with immune cell infiltration patterns

  • Correlate SERPINB4 expression/mutation status with clinical responses to checkpoint inhibitors

• Mechanistic investigations:

  • Use co-immunoprecipitation with SERPINB4 antibodies to identify binding partners in the context of granzyme inhibition

  • Implement ChIP-seq studies to identify potential transcriptional regulators of SERPINB4 in responders versus non-responders

  • Perform immunoblotting to evaluate SERPINB4's inhibitory effects on granzyme activity in tumor cell lines

• Translational applications:

  • Develop tissue microarray analysis protocols using SERPINB4 antibodies for high-throughput screening of patient samples

  • Establish standardized IHC scoring systems for SERPINB4 expression that correlate with immunotherapy outcomes

  • Implement liquid biopsy techniques to detect circulating SERPINB4 as a potential non-invasive biomarker

This research is particularly significant as SERPINB4 mutations may exert an immunogenic effect that helps initiate broad immune responses that can later be reinvigorated through checkpoint blockade .

What experimental approaches can effectively measure SERPINB4's inhibitory activity against proteases?

To effectively measure SERPINB4's inhibitory activity against its target proteases, researchers should employ the following methodological approaches:

• Enzyme kinetic assays:

  • Utilize fluorogenic or chromogenic substrates specific for chymotrypsin-like serine proteases (SERPINB4's targets)

  • Design experiments with varying concentrations of purified SERPINB4 protein to determine IC₅₀ values

  • Perform Michaelis-Menten kinetics to determine inhibition constants (Ki) and inhibition mechanisms

  • Compare with SERPINB3 inhibition profiles to confirm specificity differences

• Complex formation analysis:

  • Implement SDS-PAGE under non-reducing conditions to visualize SERPINB4-protease complexes

  • Perform Western blotting with SERPINB4 antibodies to detect these complexes specifically

  • Use gel shift assays to identify the formation of SDS-stable complexes characteristic of serpin-protease interactions

• Advanced structural biology approaches:

  • Conduct co-crystallization studies of SERPINB4 with target proteases

  • Implement hydrogen-deuterium exchange mass spectrometry to identify interaction interfaces

  • Perform site-directed mutagenesis of the RCL region to confirm the importance of specific residues in protease targeting

• Cellular activity assays:

  • Develop cell-based assays using SERPINB4-overexpressing or knockout cells

  • Measure granzyme-mediated apoptosis in control versus SERPINB4-expressing cells

  • Implement confocal microscopy with fluorescently labeled proteases to visualize inhibition in real-time

When designing these experiments, researchers should pay particular attention to the "variable region" from P7 to P5' in the RCL of SERPINB4, which dictates its specificity for chymotrypsin-like serine proteases including Chymase, Cathepsin G, and Der P .

How can SERPINB4 expression profiles be effectively correlated with clinical outcomes in cancer research?

To establish robust correlations between SERPINB4 expression and clinical outcomes in cancer research, researchers should implement a comprehensive methodological approach:

• Standardized tissue analysis protocols:

  • Develop tissue microarray (TMA) analysis with anti-SERPINB4 antibodies at validated dilutions (1:100 for paraffin sections)

  • Implement digital pathology quantification methods for objective SERPINB4 expression scoring

  • Stratify expression levels using quartiles or established cutoff values based on receiver operating characteristic (ROC) analysis

  • Combine with markers for tumor subtyping and immune infiltration

• Clinical correlation methodology:

  • Design prospective studies with uniform sample collection protocols and time points

  • Implement multivariate analysis controlling for known prognostic factors

  • Perform Kaplan-Meier survival analysis stratified by SERPINB4 expression levels

  • Calculate hazard ratios using Cox proportional hazards models

• Mutation analysis integration:

  • Correlate SERPINB4 expression with mutation status, particularly in melanoma where mutations are associated with immunotherapy response

  • Implement targeted sequencing panels that include SERPINB4 coding regions

  • Develop mutation-specific antibodies for immunohistochemical detection where possible

• Multi-omics integration:

  • Correlate protein expression data from antibody-based methods with transcriptomic data

  • Account for post-translational modifications that may affect SERPINB4 function

  • Integrate with immune profiling data to establish relationships with tumor microenvironment

When interpreting results, researchers should consider that SERPINB4 expression significantly decreases in regional lymph nodes and metastatic sites compared to primary tumors, suggesting potential immuno-editing or gene silencing during metastasis . This dynamic expression pattern should be accounted for when designing studies correlating SERPINB4 with clinical outcomes.

What is the current understanding of SERPINB4's role in modulating immune responses against tumor cells?

The current understanding of SERPINB4's immunomodulatory functions in cancer is evolving rapidly. Methodologically, researchers investigating this area should consider:

• Mechanisms of immune evasion:

  • SERPINB4 directly inhibits human granzyme proteolytic activity, with overexpression in HeLa cells demonstrating inhibition of both recombinant granzyme-induced and NK cell-mediated cell death

  • This inhibitory function may represent a key mechanism by which cancer cells evade immune surveillance

  • When designing experiments to study this phenomenon, researchers should implement co-culture systems with immune effector cells and cancer cells with modulated SERPINB4 expression

• Paradoxical role in immunotherapy:

  • Contrary to its immune-evasive functions, mutations in SERPINB4 are associated with improved survival following anti-CTLA4 immunotherapy in melanoma patients

  • This suggests that mutant forms of SERPINB4 may enhance immunogenicity rather than suppress it

  • Experimental designs should include both wild-type and mutant SERPINB4 expression systems to compare immunogenic effects

• Homology with model antigens:

  • SERPINB4 shares sequence similarity with chicken ovalbumin (OVA), a classic model antigen

  • Many SERPINB4 mutations occur within regions of homology with OVA, potentially creating neo-epitopes that enhance recognition by the adaptive immune system

  • Epitope prediction algorithms combined with MHC binding assays should be implemented to identify potential immunogenic peptides derived from mutant SERPINB4

• Expression dynamics during cancer progression:

  • SERPINB4 expression is downregulated in regional lymph nodes and metastatic sites compared to primary tumors

  • This suggests potential immuno-editing or gene silencing during metastasis

  • Longitudinal sampling and analysis should be incorporated into study designs to capture these dynamic changes

When studying SERPINB4's immunomodulatory functions, researchers should utilize complementary approaches including in vitro functional assays, in vivo tumor models, and clinical sample analysis to build a comprehensive understanding of its complex role in tumor immunity.

How are SERPINB4 antibodies being used to investigate its potential role as a biomarker in inflammatory diseases?

SERPINB4 antibodies are increasingly being utilized to explore its potential as a biomarker in inflammatory conditions, beyond its established role in cancer. Methodological approaches in this emerging research area include:

• Inflammatory disease tissue profiling:

  • Implementation of standardized immunohistochemistry protocols using SERPINB4 antibodies across inflammatory disease tissue banks

  • Comparative analysis of expression patterns between healthy and inflamed tissues

  • Correlation of expression levels with disease severity metrics and treatment responses

  • Development of multiplexed immunofluorescence panels that include SERPINB4 alongside established inflammatory markers

• Autoimmunity connections:

  • Investigation of SERPINB4's homology with ovalbumin and potential role in autoimmune conditions

  • Examination of serpin polymer formation using conformation-specific antibodies

  • Analysis of SERPINB4's potential role in autophagy induction and auto-antigen presentation

  • Correlation of serum autoantibodies against SERPINB4 with disease progression

• Non-invasive biomarker development:

  • Standardization of ELISA-based detection methods for circulating SERPINB4 in patient serum

  • Correlation of serum levels with tissue expression and clinical parameters

  • Longitudinal monitoring during disease progression and treatment response

  • Integration with other established inflammatory biomarkers in multivariate models

• Functional relevance in inflammation:

  • Investigation of SERPINB4's inhibitory effects on inflammatory proteases

  • Analysis of its potential role in modulating immune cell function and inflammatory signaling

  • Examination of expression in various immune cell populations using flow cytometry

  • Study of potential interaction with inflammasome components using co-immunoprecipitation techniques

When designing studies in this area, researchers should consider that SERPINB4 mutations can cause protein misfolding and self-polymerization, leading to the formation of inflammatory aggregates that may function as targets in various autoimmune diseases including systemic lupus erythematosus and psoriasis .

What are the technical considerations when using SERPINB4 antibodies for studying its genetic variants and mutations?

When investigating SERPINB4 genetic variants and mutations, researchers should implement tailored technical approaches to overcome specific challenges:

• Mutation-specific detection strategies:

  • Development of custom antibodies against common SERPINB4 mutations, particularly those within the RCL region

  • Implementation of epitope mapping to confirm antibody recognition sites

  • Validation using recombinant proteins expressing specific mutations

  • Development of proximity extension assays for detecting conformational changes resulting from mutations

• Variant discrimination techniques:

  • For closely related variants, implement immunoprecipitation followed by mass spectrometry

  • Develop allele-specific PCR prior to protein analysis to correlate genotype with protein expression

  • Use of CRISPR-engineered cell lines expressing specific SERPINB4 variants as controls

  • Implementation of digital PCR for precise quantification of variant expression

• Structural impact assessment:

  • Implement circular dichroism (CD) spectroscopy following immunopurification with SERPINB4 antibodies

  • Analyze thermal stability of variant proteins compared to wild-type

  • Assess propensity for polymer formation using size exclusion chromatography

  • Evaluate impact on serpin inhibitory mechanism using activity assays against target proteases

• Clinical sample analysis:

  • Develop tissue preservation protocols that maintain epitope integrity for mutation-specific antibodies

  • Implement laser capture microdissection to isolate specific cell populations for mutation analysis

  • Design multiplex immunofluorescence panels to correlate mutation status with microenvironmental features

  • Establish bioinformatic pipelines for integrating genomic, transcriptomic, and proteomic data

This approach is particularly relevant given the finding that mutations in SERPINB3/B4 are associated with survival following anti-CTLA4 immunotherapy, with many of the observed mutations occurring within regions homologous to ovalbumin that potentially serve as T cell epitopes .